AR085575A1 - Formulaciones de anticuerpos - Google Patents
Formulaciones de anticuerposInfo
- Publication number
- AR085575A1 AR085575A1 ARP120101010A AR085575A1 AR 085575 A1 AR085575 A1 AR 085575A1 AR P120101010 A ARP120101010 A AR P120101010A AR 085575 A1 AR085575 A1 AR 085575A1
- Authority
- AR
- Argentina
- Prior art keywords
- sodium
- acetate
- potassium
- ammonium
- crystal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un cristal de un anticuerpo de IgG antiescleroso que comprende regiones variables de cadenas ligeras y pesadas de SEQ ID Nº 3 y 5, que tengan preferentemente las secuencias de aminoácidos de SEQ ID Nº 13 y 15.Reivindicación 2: Una fórmula estéril que comprende un cristal de un anticuerpo de IgG antiescleroso, caracterizado porque al menos 70% del anticuerpo tiene forma cristalina. Reivindicación 8: El cristal o la fórmula de cualquiera de las reivindicaciones anteriores, caracterizadas porque el cristal contiene una sal seleccionada de un grupo que contiene fosfato dihidrógeno de sodio, fosfato hidrógeno dipotásico, cloruro de sodio, sulfato de amonio, tartrato tetrahidrato de sodio y potasio, tacsimato, citrato de sodio dihidrato, acetato de sodio trihidrato, tartrato diamónico, malonato de sodio, acetato, acetato de calcio, cacodilato, CHES, sulfato de litio, cloruro de magnesio, acetato de zinc, cloruro de cesio, fosfato de amonio, fosfato de sodio, fosfato de potasio, fluoruro de sodio, ioduro de potasio, ioduro de sodio, ioduro de amonio, tiocianato de sodio, tiocianato de potasio, formiato de sodio, formiato de potasio y formiato de amonio. Reivindicación 15: Las fórmulas de las reivindicaciones 11 ó 12, que, al ser administradas a sujetos mamíferos, medien un aumento en la densidad mineral ósea que es al menos de aproximadamente 70% del nivel de densidad mineral ósea mediada por una fórmula líquida de dicho anticuerpo que no ha sido cristalizado, caracterizada porque la fórmula y la fórmula líquida del anticuerpo que no ha sido cristalizada se administra al sujeto en la misma dosis y en el mismo modo. Reivindicación 18: Un envase que comprende al menos 50 mg del cristal de anticuerpo de la reivindicación 1 para su suspensión en un volumen de 0,5 - 2 mL. Reivindicación 24: Un método para producir un cristal de un anticuerpo de IgG antiescleroso, que comprende regiones variables de cadenas ligeras y pesadas de SEQ ID Nº 3 y 5, preferentemente que tenga las secuencias de aminoácidos de SEQ ID Nº 13 y 15, el método que comprende la combinación de una solución del anticuerpo con un reactivo de cristalización, que consiste en una sal seleccionada de un grupo que contiene fosfato dihidrógeno de sodio, fosfato hidrógeno dipotásico, cloruro de sodio, sulfato de amonio, acetato de amonio, tartrato tetrahidrato de sodio y potasio, tacsimato, citrato de sodio dihidrato, acetato de sodio trihidrato, tartrato diamónico, malonato de sodio, acetato, acetato de calcio, cacodilato, CHES, sulfato de litio, acetato dihidrato de litio, cloruro de magnesio, acetato tetrahidrato de magnesio, formiato de magnesio, nitrato de magnesio, sulfato de magnesio, acetato de zinc, cloruro de zinc, sulfato de zinc, cloruro de cesio, fosfato de amonio, fosfato de sodio, fosfato de potasio, fluoruro de sodio, ioduro de potasio, ioduro de sodio, ioduro de amonio, tiocianato de sodio, tiocianato de potasio, formiato de sodio, formiato de potasio y formiato de amonio, opcionalmente a un pH de alrededor de 6 hasta aproximadamente 8, de modo tal que se forme el cristal. Reivindicación 31: Un método para incrementar la densidad mineral ósea, tratando desórdenes asociados con una densidad ósea disminuida, tratando un desorden relacionado con los huesos, o mejorando los resultados en un procedimiento, reemplazo, injerto, cirugía o reparación en un sujeto mamífero, que comprende la administración de la fórmula de una de las reivindicaciones de 2 a 17 en una cantidad efectiva para así incrementar la densidad mineral ósea del sujeto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161467868P | 2011-03-25 | 2011-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085575A1 true AR085575A1 (es) | 2013-10-09 |
Family
ID=45922852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101010 AR085575A1 (es) | 2011-03-25 | 2012-03-26 | Formulaciones de anticuerpos |
Country Status (24)
Country | Link |
---|---|
US (3) | US9145457B2 (es) |
EP (1) | EP2688910B1 (es) |
JP (2) | JP2014511842A (es) |
KR (1) | KR20140018315A (es) |
CN (1) | CN103517920B (es) |
AP (1) | AP3981A (es) |
AR (1) | AR085575A1 (es) |
AU (1) | AU2012236962B2 (es) |
BR (1) | BR112013024493A2 (es) |
CA (1) | CA2830538C (es) |
CL (1) | CL2013002743A1 (es) |
CO (1) | CO6801637A2 (es) |
CR (1) | CR20160147A (es) |
EA (1) | EA029956B1 (es) |
IL (1) | IL228455A (es) |
MA (1) | MA35009B1 (es) |
MX (1) | MX338078B (es) |
MY (1) | MY170720A (es) |
PE (1) | PE20140437A1 (es) |
SG (2) | SG10201701634PA (es) |
TN (1) | TN2013000378A1 (es) |
TW (1) | TW201247703A (es) |
WO (1) | WO2012135035A1 (es) |
ZA (2) | ZA201307122B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
EP3207059A1 (en) * | 2014-10-17 | 2017-08-23 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies |
AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
CN107090443B (zh) * | 2016-02-18 | 2020-12-08 | 中国农业大学 | 一种制备稻瘟病菌促分裂原活化蛋白激酶MoMps1晶体的方法 |
CN105777858B (zh) * | 2016-03-22 | 2019-09-10 | 东软威特曼生物科技(南京)有限公司 | 多种抗体的复合稳定剂及其使用方法 |
US10279048B2 (en) * | 2016-07-13 | 2019-05-07 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
TW201909913A (zh) * | 2017-07-27 | 2019-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種sost抗體醫藥組成物及其用途 |
CN109112153A (zh) * | 2018-09-03 | 2019-01-01 | 浙江善测禾骑士生物科技有限公司 | 一种lpor-y193f突变体蛋白晶体的制备方法 |
BR112021008122A8 (pt) * | 2018-10-31 | 2023-01-31 | Merck Sharp & Dohme | Cristais de anticorpo anti-pd-1 humano e métodos de uso dos mesmos |
EP3653702A1 (en) * | 2018-11-15 | 2020-05-20 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Crystal structure of a replication protein encoded by a plasmid isolated from a multiple sclerosis patient |
CN113444800A (zh) * | 2021-06-30 | 2021-09-28 | 北京泱深生物信息技术有限公司 | 基因群作为共预后因子在肾癌预后检测中的应用 |
CN115804338A (zh) * | 2022-12-19 | 2023-03-17 | 新疆农业科学院经济作物研究所 | 一种海岛棉育种方法 |
CN116375864B (zh) * | 2023-05-16 | 2023-08-08 | 成都大熊猫繁育研究基地 | 一种抗大熊猫amh单克隆抗体、杂交瘤细胞株及其应用 |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗hiv改変抗体および改変抗体の調製方法 |
US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
JPH06502311A (ja) | 1990-10-22 | 1994-03-17 | フォックス・チェイス・キャンサー・センター | Rna療法を提供するためのdna構造 |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
WO1994028929A1 (en) | 1993-06-07 | 1994-12-22 | Genentech, Inc. | Hiv envelope polypeptides |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
EP0756628B1 (en) | 1994-04-29 | 2007-11-14 | Curis, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
JPH10503179A (ja) | 1994-06-24 | 1998-03-24 | イミュネックス・コーポレーション | 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法 |
DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
IL112834A (en) | 1995-03-01 | 2000-12-06 | Yeda Res & Dev | Pharmaceutical compositions for controlled release of soluble receptors |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
WO1997044461A2 (en) | 1996-05-22 | 1997-11-27 | Novopharm Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
WO1998046588A2 (en) | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US6020004A (en) | 1997-04-17 | 2000-02-01 | Amgen Inc. | Biodegradable microparticles for the sustained delivery of therapeutic drugs |
ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
EP1000152A2 (en) | 1997-08-01 | 2000-05-17 | Genset | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES |
US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
US6432449B1 (en) | 1998-05-18 | 2002-08-13 | Amgen Inc. | Biodegradable sustained-release alginate gels |
US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
MXPA01005275A (es) | 1998-11-27 | 2003-06-06 | Darwin Discovery Ltd | Composiciones y metodos para aumentar la mineralizacion de huesos. |
US6451346B1 (en) | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
CN1345334A (zh) | 1999-01-29 | 2002-04-17 | 伊姆克罗尼系统公司 | 对kdr特异的抗体及其应用 |
EP1683811B1 (en) | 1999-06-09 | 2009-08-19 | Genentech, Inc. | Methods for the diagnosis of tumors |
JP2003525611A (ja) | 2000-03-02 | 2003-09-02 | アムジェン インコーポレーテッド | コルディン様−2分子およびその使用 |
AU2001265198A1 (en) | 2000-06-01 | 2001-12-11 | Amgen Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
JP2004520005A (ja) | 2000-06-19 | 2004-07-08 | エフ.ホフマン−ラ ロシュ アーゲー | オステオレビン遺伝子多型性 |
AU2002216610A1 (en) | 2000-09-01 | 2002-04-02 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
ATE442862T2 (de) | 2000-10-12 | 2009-10-15 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
AU2002256971B2 (en) * | 2000-12-28 | 2008-04-03 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
DE10145772A1 (de) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
NZ533051A (en) | 2001-12-06 | 2006-10-27 | Biocontrol Systems Inc | Sample collection and testing system |
US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
US7332276B2 (en) | 2002-03-01 | 2008-02-19 | Celltech R&D, Inc. | Methods to increase or decrease bone density |
US7799523B2 (en) | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
US20040023356A1 (en) | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
EP1572122A4 (en) | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | METHOD FOR PREVENTING INFECTIONS FROM BIOLOGICAL TERRORISM AGENTS WITH IMMUNOSTIMULATORY CPG OLIGONUCLEOTIDES |
US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
ES2379689T3 (es) | 2003-03-14 | 2012-04-30 | Ucb Manufacturing, Inc. A Company Incorporated Under The Laws Of The State Of Delaware | Complejo de esclerostina y nogina o cordina, y agentes que modulan la formación de dicho complejo |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
ES2586401T3 (es) | 2003-06-16 | 2016-10-14 | Ucb Pharma S.A. | Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea |
US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
ZA200700947B (en) * | 2004-07-23 | 2008-06-25 | Genentech Inc | Crystallization of antibodies or fragments thereof |
MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US8541177B2 (en) | 2006-01-13 | 2013-09-24 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
EP2423226A3 (en) | 2006-11-10 | 2012-05-30 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
LT3345607T (lt) | 2006-12-29 | 2023-01-10 | Ossifi-Mab Llc | Kaulų augimo keitimo būdai, skiriant sost arba wise antagonistą ar agonistą |
BRPI0807205A2 (pt) | 2007-02-02 | 2014-07-22 | Novartis Ag | Moduladores de ligantes esclerostina para tratamento de distúrbios relacionados ao osso |
EP2131860B1 (en) | 2007-03-20 | 2013-12-18 | Eli Lilly & Company | Anti-sclerostin antibodies |
WO2008121301A1 (en) * | 2007-03-29 | 2008-10-09 | Abbott Laboratories | Crystalline anti-human il-12 antibodies |
EP2185201A4 (en) | 2007-08-08 | 2011-11-30 | Abbott Lab | COMPOSITIONS AND METHODS FOR CRYSTALLIZING ANTIBODIES |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
MX2010004761A (es) | 2007-11-02 | 2010-05-19 | Novartis Ag | Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6). |
CN101896201A (zh) | 2007-12-14 | 2010-11-24 | 安进公司 | 使用抗硬骨素抗体治疗骨折的方法 |
SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
AR075715A1 (es) | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
EP2632951B1 (en) | 2010-10-27 | 2017-08-02 | Amgen Inc. | Dkk1 antibodies and methods of use |
US9657090B2 (en) | 2011-12-28 | 2017-05-23 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
-
2012
- 2012-03-23 KR KR20137028039A patent/KR20140018315A/ko not_active Application Discontinuation
- 2012-03-23 WO PCT/US2012/030364 patent/WO2012135035A1/en active Application Filing
- 2012-03-23 JP JP2014501280A patent/JP2014511842A/ja active Pending
- 2012-03-23 PE PE2013002107A patent/PE20140437A1/es not_active Application Discontinuation
- 2012-03-23 SG SG10201701634PA patent/SG10201701634PA/en unknown
- 2012-03-23 BR BR112013024493-3A patent/BR112013024493A2/pt not_active IP Right Cessation
- 2012-03-23 MX MX2013011012A patent/MX338078B/es active IP Right Grant
- 2012-03-23 CA CA2830538A patent/CA2830538C/en active Active
- 2012-03-23 CN CN201280021111.XA patent/CN103517920B/zh active Active
- 2012-03-23 EP EP12711543.4A patent/EP2688910B1/en active Active
- 2012-03-23 MY MYPI2013003468A patent/MY170720A/en unknown
- 2012-03-23 US US14/006,010 patent/US9145457B2/en active Active
- 2012-03-23 AP AP2013007135A patent/AP3981A/en active
- 2012-03-23 SG SG2013071733A patent/SG193610A1/en unknown
- 2012-03-23 AU AU2012236962A patent/AU2012236962B2/en active Active
- 2012-03-23 CR CR20160147A patent/CR20160147A/es unknown
- 2012-03-23 EA EA201391389A patent/EA029956B1/ru not_active IP Right Cessation
- 2012-03-23 MA MA36279A patent/MA35009B1/fr unknown
- 2012-03-26 TW TW101110431A patent/TW201247703A/zh unknown
- 2012-03-26 AR ARP120101010 patent/AR085575A1/es unknown
-
2013
- 2013-09-16 IL IL228455A patent/IL228455A/en active IP Right Grant
- 2013-09-20 ZA ZA2013/07122A patent/ZA201307122B/en unknown
- 2013-09-23 CO CO13225444A patent/CO6801637A2/es not_active Application Discontinuation
- 2013-09-24 TN TNP2013000378A patent/TN2013000378A1/fr unknown
- 2013-09-25 CL CL2013002743A patent/CL2013002743A1/es unknown
-
2015
- 2015-08-21 US US14/832,268 patent/US9617333B2/en active Active
-
2016
- 2016-12-15 ZA ZA2016/08660A patent/ZA201608660B/en unknown
-
2017
- 2017-02-03 JP JP2017018015A patent/JP6412964B2/ja active Active
- 2017-03-16 US US15/460,961 patent/US9920114B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR085575A1 (es) | Formulaciones de anticuerpos | |
Yao et al. | Biomineralization: from material tactics to biological strategy | |
Giocondi et al. | Molecular mechanisms of crystallization impacting calcium phosphate cements | |
RU2013156980A (ru) | Соединения и композиции для стабилизации индуцируемого гипоксией фактора-2 альфа как способ лечения рака | |
IL172513A0 (en) | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | |
JP2019525962A (ja) | ケモカイン受容体調節剤及びそれの使用 | |
JP2010513522A5 (es) | ||
BR112020007536A2 (pt) | anticorpos anti-tau e seus usos | |
JP2015522265A (ja) | 少なくとも2つの異なる標的化実体を含むテーラーメイドで選択的かつ多重特異性治療用分子を選択および作製するための方法およびその使用 | |
JP2016517442A (ja) | eIF2α経路の調節因子 | |
MX2015004524A (es) | Metodos y composiciones de nanoplacas de plata. | |
JP2013538796A5 (es) | ||
AR075411A1 (es) | Derivados de triazolo[1,5-a]piridina como inhibidores de kinasa. | |
AR085285A1 (es) | Metodos para tratar enfermedades de la retina | |
AR053012A1 (es) | Polimorfo a de ibandronato | |
JP2012526148A5 (es) | ||
JP2013528570A5 (es) | ||
JP2017525680A5 (es) | ||
Gałęzowska | Interactions between clinically used bisphosphonates and bone mineral: From coordination chemistry to biomedical applications and beyond | |
US20220267435A1 (en) | Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting | |
AR079524A1 (es) | Cianobutiratos sustituidos con accion herbicida, proceso para prepararlos, composicion herbicida que los contiene y metodo para controlar vegetacion indeseada | |
CA3012196A1 (en) | Anti-egfr antibody drug conjugate | |
EP3897622A1 (en) | Arginase inhibitors and methods of use | |
BRPI0917147B8 (pt) | composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto | |
Rivas et al. | An experimental-computer modeling study of inorganic phosphates surface adsorption on hydroxyapatite particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |